Covidien, a leading global provider of healthcare products and recognized innovator in patient monitoring and respiratory care devices, today launched the Capnostream 20p bedside monitor. The new capnography solution, with Covidien’s Microstream technology...
Covidien will present several advanced healthcare solutions for addressing enhanced patient care and safety at Anesthesiology 2013, the American Society of Anesthesiologists (ASA) annual meeting. At the event, held October 12-16 in San Francisco...
California medical device maker Ivera Medical announced a 2nd lawsuit against Covidien, this time in a district court in Southern California, claiming infringement of patents for disinfecting caps for medical devices. The new lawsuit alleged infringement of a 4th patent...
Covidien said its board of directors authorized a restructuring plan aimed at saving up to $300 million a year by fiscal 2018, with manufacturing and distribution operations slated to be closed. Covidien did not reveal how many layoffs would be involved.
Medical device giant Covidien is at the center of a new infringement lawsuit accusing the company of violating a trio of Ivera Medical patents for technologies used to clean and disinfect certain valves and IV connectors. The devices in question are small caps that fit over the ends of needle-less IV connectors...
Massachusetts medical device maker Covidien is opening the doors on a new Center of Innovation in South Korea, a country that the company calls "a key market in our global strategy." Covidien plans to spend $21 million over the course of 3 years to support the center...
Covidien (NYSE: COV), a leading global provider of healthcare products, today announced the opening of the Covidien Center of Innovation Korea (CCI Korea), its first research & development (R&D) and training & education center in Korea. With a total investment of US$21 million over a three year period, CCI Korea is a high-tech medical training center focused on raising awareness of various disease states...
Covidien recalled some lots of its Monoject syringes after discovering a sterilization mishap and labeling problem. The issues affected 14 lots in shipments that went out to customers in the U.S. and Bermuda, the Mansfield, Mass.-based medical products giant said.
CAS Medical (NSDQ:CASM) won a round in a legal battle with Covidien's (NYSE:COV) Nellcor patient monitoring subsidiary over technology used to measure oxygen levels in the brain, after a federal judge in Michigan tossed a breach-of-contract claim against CasMed.
Covidien kicked off 2 new clinical trials this week to support a global evaluation of its Stellarex drug-coated angioplasty balloon. The Massachusetts-based company started enrolling patients with peripheral arterial disease in the Pivotal and PK arms of its larger ILLUMENATE clinical trials examining the safety and effectiveness of Covidien's Stellarex devices.
Covidien, a leading global provider of healthcare products and recognized innovator in patient monitoring and respiratory care devices, has released a new interface making the INVOS™ cerebral oximetry system compatible with the Nuvon System. The technology allows hospitals to integrate patient data with Electronic Medical Record (EMR) systems.
The U.S. tax agency has informed Tyco International Ltd. that it has disallowed roughly $2.86 billion in interest and deductions recognized by the company in its tax returns for the 1997-2000 tax years, according to a filing with the Securities and Exchange Commission.
Covidien could wind up stuck with its share of a $1.07 billion tax bill, after the IRS told its former corporate parent, Tyco International, that tax deductions it took from 1997 to 2000 will be disallowed, according to a regulatory filing.
Covidien, a leading global provider of healthcare products, today announced it has completed the separation of its Pharmaceuticals business, which is now held by Mallinckrodt plc, a new independent company. Mallinckrodt will begin “regular way” trading on the New York Stock Exchange today under the symbol "MNK."
Covidien (NYSE:COV), a leading global provider of healthcare products, today announced that the final results of the PUFs (Pipeline for Uncoilable or Failed Aneurysms) clinical study of its Pipeline™ embolization device have been published in the June issue of Radiology. Radiology is the official peer-reviewed medical journal of the Radiological Society of North America.
Covidien (NYSE: COV), a leading global provider of healthcare products, has announced that an independent study conducted by the University of Edinburgh has successfully demonstrated the effectiveness of Covidien’s Kendall SCD™ system with Vascular Refill Detection Technology on immobile stroke patients.
In today’s medical facilities, healthcare providers face heavy workloads and care for more patients with decreased clinical staff. They need products and technologies that help them provide effective care as efficiently as possible. At Covidien, our goal is to provide monitoring solutions that enhance patient care in a range of clinical environments.
Next-Generation Clot Retrieval Technology Improves Patient Outcomes vs. First- Generation Devices, Say Leading Stroke PhysiciansJune 11, 2013 11:59 am | by Covidien | News | Comments
Covidien brought together six of the world’s prominent thought-leaders in stroke at the 2013 European Stroke Conference. At a Covidien-sponsored symposium, the stroke experts presented and discussed data underscoring the benefits of endovascular therapy in treating acute ischemic stroke and, particularly, the important role that new devices play when this procedure is performed to remove blood clots from large vessels in the brain.
The technology at the heart of the next generation of medical devices is critical to our ability to offer comprehensive care in the coming decades. While our current systems of care have served us well thus far, they are crumbling under the pressures of modern expectations of care, economics, scale, and the sheer breadth of medical science.
Covidien Nellcor Pulse Oximeters Receive FDA 510(k) Clearance with Labeling for Use in Newborn Screening for Critical Congenital Heart DiseaseMay 28, 2013 12:35 pm | by Covidien | News | Comments
Covidien’s new CCHD labeling was introduced as part of the FDA 510(k)-cleared labeling for motion tolerant Nellcor pulse oximeters. In 2011, the U.S. Department of Health and Human Services added CCHD screening to the Federal Recommended Uniform Screening Panel Guidelines.
Covidien’s Technology Platform to Diagnose Early Lung Cancer Part of New Guidelines of American College of Chest PhysiciansMay 21, 2013 6:59 am | by The Associated Press | News | Comments
MINNEAPOLIS--(BUSINESS WIRE)--May 21, 2013--Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that its superDimension Electromagnetic Navigation Bronchoscopy (ENB™) system, the first technology of its kind, is included in the new American College of Chest...
Covidien, a leading global provider of healthcare products and recognized innovator in patient monitoring and respiratory care devices, today announced that its Nellcor™ pulse oximetry portfolio, which is used to measure arterial oxygen saturation, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for motion claims.
Gain best practices in overcoming international labeling challenges at the Medical Device Global Labeling Strategies Conference, July 24-25, 2013 in Minneapolis, MN. This premier marcus evans event will bring together leading medical device labeling professionals to discuss how to successfully create a label on both a national and international scale.
Covidien, a leading global provider of healthcare products and recognized innovator in patient monitoring and respiratory care devices, has launched the Microstream® MicroPod™ module. This is an important product for its Original Equipment Manufacturer (OEM) partners that will help hospitals improve patient safety by expanding access to capnography technology.
Massachusetts-based medical device maker Covidien announced a voluntary recall of certain Power Pac batteries distributed with its Newport HT70 and HT70 Plus ventilators, according to an FDA notice. Covidien launched the recall in response to reports that some batteries were resorting to back-up power sooner than expected while operating on the Power Pac battery.